Company intelligence / Profile preview

PuriBlood Medical

Hsinchu City, Taiwan

Ownership: Private
Employees: ~44
Development stage: Other

Overview

PuriBlood Medical has commercialized leukocyte reduction filters with demonstrated >99.99% efficiency in leukocyte removal from blood while maintaining high erythrocyte recovery; multiple academic studies confirm improved anti-biofouling and hemocompatibility compared to conventional filters[3].

Therapeutic areas: NephrologyHematology
Modalities: DeviceBiologic (specifically membrane technology)
Industry: Therapeutic Medical Devices

Partnerships

Collaborations with R&D center for membrane technology (RDCMT)clinicianshospitals

Beyond the preview

Go deeper on PuriBlood Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PuriBlood Medical.

Explore the full profile